Silver Book Fact

Use of existing or new drugs/compounds for Alzheimer’s prevention could result in a delay of onset of between 2 and 5 years.

Shekelle, Paul G., Eduardo Ortiz, Sydne J. Newberry, Michael W. Rich, Shannon L. Rhodes, Robert H. Brook, and Dana P. Goldman. Identifying Potential Health Care Innovations for the Elderly of the Future: Health and costs of the future elderly. Health Aff. 2005; 24(2). https://www.ncbi.nlm.nih.gov/pubmed/16186152

Reference

Title
Identifying Potential Health Care Innovations for the Elderly of the Future: Health and costs of the future elderly
Publication
Health Aff
Publication Date
2005
Authors
Shekelle, Paul G., Eduardo Ortiz, Sydne J. Newberry, Michael W. Rich, Shannon L. Rhodes, Robert H. Brook, and Dana P. Goldman
Volume & Issue
Volume 24, Issue 2
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, 42 medicines are currently in development for Alzheimer’s disease.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 Medicare costs for people with the disease would be…  
  • In one study, Alzheimer’s patients who took donepezil had an increase in their prescription costs of $1,000 per patient, but saw reduced total medical costs of about 1/3–from $11,947 to…  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 total cost of care (for all payers) for all people…  
  • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…